# Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis

> **NCT01688024** · PHASE2 · UNKNOWN · sponsor: **Li, Zhiping, M.D.** · enrollment: 130 (estimated)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Mitomycin C
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT01688024
- **Lead sponsor:** Li, Zhiping, M.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09
- **Primary completion:** 2017-09
- **Final completion:** 2019-09
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2016-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01688024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01688024, "Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01688024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*